141
Participants
Start Date
May 4, 2021
Primary Completion Date
November 30, 2022
Study Completion Date
December 10, 2022
AUR101
Oral ROR-gamma inverse agonist
Placebo
Placebo
The Dermatology Specialists, New York
Sadick Research Group, New York
Paddington Testing Co, Inc, Philadelphia
Accel Research Sites - Deland CRU, DeLand
Direct Helpers Research Center, Hialeah
Abys New Generation Research Inc., Hialeah
FXM Clinical Research Miramar LLC, Miramar
Skin Research Institute, Coral Gables
Lenus Research & Medical Group, LLC, Sweetwater
FXM Clinical Research Miami LLC, Miami
Floridian Reserach, Miami
FXM Clinical Research Fort Lauderdale, Fort Lauderdale
Moore Clinical Research, Inc., Brandon
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Great Lakes Research Group, Inc, Bay City
Medisearch Clinical Trials, Saint Joseph
Northwest AR Clinical Trials Center, Rogers
Johnson Dermatology, Fort Smith
Dermatology Treatment & Research Center, Dallas
Center for Clinical Studies Ltd., LLP., Webster
Dermatology Research Associates, Los Angeles
Clinical Science Institute, Santa Monica
Unison Clinical Trials, Sherman Oaks
University Clinical Trials, Inc., San Diego
First OC Dermatology, Fountain Valley
Lead Sponsor
Aurigene Discovery Technologies Limited
INDUSTRY